Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 44

Sort by

Sort Order Select

Journal Articles

Carfilzomib, Pomalidomide, Dexamethasone with and without Daratumumab in Relapsed/Refractory Multiple Myeloma: A Multi-Center, Prospective Real World Study in China

Fujing Zhang, Wei Wang, Hua Wang, Wei Wang, Aijun Liu, Weiwei Tian, Xiaoqi Qin, Zhongjun Xia, Junling Zhuang

Blood (2024) 144 (Supplement 1): 6985.

https://doi.org/10.1182/blood-2024-209342

Published: 2024

Journal Articles

Ixazomib Based Regimens As Front-Line Treatment in Newly Diagnosed Multiple Myeloma Patients in China: A Real-World Data from Infinite Study

Fu Cheng Cheng, Song Jin, Junling Zhuang, Xin Zhou, Fan Zhou, Yuhua Li, Kaiyang Ding, Ting Niu, Wenming Chen, Baijun Fang, Li-Li Chen, Rong Fu, Hao Zhang, Jiaping Fu, Xiuju Wang, Sha Liu, Lin Li, Depei Wu

Blood (2024) 144 (Supplement 1): 6970.

https://doi.org/10.1182/blood-2024-204366

Published: 2024

Journal Articles

YM155 Exerts Anti-Myeloma Effects Via Myc/BBC3 Signaling Pathway in Vitro

Xianghong Jin, Fujing Zhang, Huiwen He, Ziping Li, Junling Zhuang

Blood (2024) 144 (Supplement 1): 6849.

https://doi.org/10.1182/blood-2024-205692

Published: 2024

Journal Articles

The Role of Next-Generation Sequencing in Predicting Early Relapse for Newly Diagnosed Multiple Myeloma Patients Treated with VRD Regimen

Lili Cheng, Fujing Zhang, Ziping Li, Junling Zhuang, Hao Cai, Hui Li

Blood (2024) 144 (Supplement 1): 6856.

https://doi.org/10.1182/blood-2024-210092

Published: 2024

Journal Articles

Long-Term Real-World Follow-up Study of Luspatercept for Lower-Risk Myelodysplastic Neoplasms

Zhuxin Zhang, Leyu Wang, Ziwei Liu, Chen Yang, Miao Chen, Bing Han, Junling Zhuang

Blood (2024) 144 (Supplement 1): 6730.

https://doi.org/10.1182/blood-2024-199403

Published: 2024

Journal Articles

Effective Treatment of Refractory Aplastic Anemia with Romiplostim after Failure of Multiple Thrombopoietin Receptor Agonists: A Single-Center Retrospective Study

Xijuan Lin, Chen Yang, Ziwei Liu, Junling Zhuang, Miao Chen, Bing Han

Blood (2024) 144 (Supplement 1): 4077.

https://doi.org/10.1182/blood-2024-200421

Published: 2024

Journal Articles

In-Class Transition (iCT) of Proteasome Inhibitor-Based Therapy Prolongs Progression-Free Survival in High-Risk Myeloma Patients: A Real-World Chinese Cohort Study

Rong Fu, Hong Yu, Aijun Liu, Rui Hou, Zunmin Zhu, Junling Zhuang, Li Bao, Zhenling Li, Lihong Liu, Luoming Hua, Yanping Ma, Da Gao, ARong Jin, Xiaohui Suo, Wei Yang, Yuansong Bai, Deqiang Zheng, Wenming Chen

Blood (2024) 144 (Supplement 1): 7846.

https://doi.org/10.1182/blood-2024-209471

Published: 2024

Journal Articles

Ixazomib, Pomalidomide and Dexamethasone (IxaPD) Pan-Oral Regimen in the Treatment of Refractory and Relapsed Multiple Myeloma

Miao Chen, Hong Yu, Aijun Liu, Wei Wang, Xiaoqi Qin, Ziping Li, Yanping Ma, Wenming Chen, Rong Fu, Junling Zhuang

Blood (2024) 144 (Supplement 1): 7038.

https://doi.org/10.1182/blood-2024-210284

Published: 2024

Journal Articles

Post Hoc Analysis of Phase III Gecacitinib Clinical Trial Outcomes: Enhanced Understanding and Implications

Blood (2024) 144 (Supplement 1): 3165.

https://doi.org/10.1182/blood-2024-202790

Published: 2024

Journal Articles

Initial Results from a Phase 1 Study of TQB2934, a BCMA × CD3 Bispecific Antibody, As Monotherapy in Patients with Relapsed/Refractory Multiple

Peng Liu, Junling Zhuang, Zhongjun Xia, Bingzong Li, Songfu Jiang, Yian Zhang, Wei Wang, Xiaoqin Chen, Xiaohui Zhang, Shujuan Zhou

Blood (2024) 144 (Supplement 1): 1998.

https://doi.org/10.1182/blood-2024-209665

Published: 2024

Journal Articles

Clinical Characteristics and Prognostic Analysis of Non-Amyloid Monoclonal Gammopathy of Renal Significance (MGRS) in China

Yuhang Song, Yang Liu, Junru Liu, Juan Li, Jin Lu, Junling Zhuang

Blood (2024) 144 (Supplement 1): 4679.

https://doi.org/10.1182/blood-2024-206458

Published: 2024

Journal Articles

Rituximab Plus Bortezomib for Refractory and Relapsed Warm Autoimmune Hemolytic Anemia：a Prospective, Single-Arm, Phase Ⅱ Trial

Xijuan Lin, Chen Yang, Junling Zhuang, Daobin Zhou, Miao Chen, Bing Han

Blood (2023) 142 (Supplement 1): 3829.

https://doi.org/10.1182/blood-2023-178625

Published: 2023

Journal Articles

Exploration of B and T Cell Receptor Repertoires Reveals Distinct Mechanisms in Pure Red Cell Aplasia, Autoimmune Hemolytic Anemia, and Aplastic Anemia

Ruoxi Zhang, Junling Zhuang, Bing HAN

Blood (2023) 142 (Supplement 1): 5196.

https://doi.org/10.1182/blood-2023-174862

Published: 2023

Journal Articles

Adding Hetrombopag to Cyclosporine a to Patients with Newly Diagnosed Transfusion-Dependent Non-Severe Aplastic Anemia-a Prospective Phase 2 Study

Shupei Shen, Zhuxin Zhang, Junling Zhuang, Qinglin Hu, Miao Chen, Bing Han

Blood (2023) 142 (Supplement 1): 5005.

https://doi.org/10.1182/blood-2023-184471

Published: 2023

Journal Articles

Transcriptomic Profile of Peripheral Blood Mononuclear Cells in Sirolimus-Sensitive Acquired Pure Red Cell Aplasia Patients

Yuan Yang, Qinglin Hu, Chen Yang, Miao Chen, Junling Zhuang, Bing Han

Blood (2023) 142 (Supplement 1): 5199.

https://doi.org/10.1182/blood-2023-179897

Published: 2023

Journal Articles

STK10 Mutation Block Erythropoiesis in Acquired Pure Red Cell Aplasia Via Down-Regulated the Ribosome Biosynthesis

Zhangbiao Long, Jichun Yang, Xinyao Liu, Min Ruan, Danchen Meng, Junling Zhuang, Zhenqi Huang, Jian Ge, Bing Han

Blood (2023) 142 (Supplement 1): 3825.

https://doi.org/10.1182/blood-2023-189722

Published: 2023

Journal Articles

The Change of Complement Deposition after Complement Inhibitor Treatment in Paroxysmal Nocturnal Hemoglobinuria Patients

Menglu Zhang, Xuan Wang, Chen Yang, Miao Chen, Junling Zhuang, Bing Han

Blood (2023) 142 (Supplement 1): 1350.

https://doi.org/10.1182/blood-2023-178384

Published: 2023

Journal Articles

Identification of HLA Class I Alleles in Patients with Paroxysmal Nocturnal Hemoglobinuria with Different Clone Sizes

Zhuxin Zhang, Qinglin Hu, Junling Zhuang, Bing Han

Blood (2023) 142 (Supplement 1): 5632.

https://doi.org/10.1182/blood-2023-179026

Published: 2023

Journal Articles

Ixazomib, Pomalidomide and Dexamethasone (IxaPD) Pan-Oral Regimen in the Treatment of Refractory and Relapsed Multiple Myeloma

Miao Chen, Rong Fu, Wenming Chen, Wei Wang, Yanping Ma, Junling Zhuang

Blood (2023) 142 (Supplement 1): 6696.

https://doi.org/10.1182/blood-2023-187828

Published: 2023

Journal Articles

COVID-19 Vaccine Acceptance/Hesitancy and Influence on Infection in Patients with Multiple Myeloma: A National-Wide Multicenter Survey in China

Huiwen He, Ziping Li, Shuangjiao Liu, Wenming Chen, Wanling Sun, Baolai Hua, Yongzhe Li, Junling Zhuang

Blood (2023) 142 (Supplement 1): 6674.

https://doi.org/10.1182/blood-2023-174361

Published: 2023

NARROW

Carfilzomib, Pomalidomide, Dexamethasone with and without Daratumumab in Relapsed/Refractory Multiple Myeloma: A Multi-Center, Prospective Real World Study in China

Ixazomib Based Regimens As Front-Line Treatment in Newly Diagnosed Multiple Myeloma Patients in China: A Real-World Data from Infinite Study

YM155 Exerts Anti-Myeloma Effects Via Myc/BBC3 Signaling Pathway in Vitro

The Role of Next-Generation Sequencing in Predicting Early Relapse for Newly Diagnosed Multiple Myeloma Patients Treated with VRD Regimen

Long-Term Real-World Follow-up Study of Luspatercept for Lower-Risk Myelodysplastic Neoplasms

Effective Treatment of Refractory Aplastic Anemia with Romiplostim after Failure of Multiple Thrombopoietin Receptor Agonists: A Single-Center Retrospective Study

In-Class Transition (iCT) of Proteasome Inhibitor-Based Therapy Prolongs Progression-Free Survival in High-Risk Myeloma Patients: A Real-World Chinese Cohort Study

Ixazomib, Pomalidomide and Dexamethasone (IxaPD) Pan-Oral Regimen in the Treatment of Refractory and Relapsed Multiple Myeloma

Post Hoc Analysis of Phase III Gecacitinib Clinical Trial Outcomes: Enhanced Understanding and Implications

Initial Results from a Phase 1 Study of TQB2934, a BCMA × CD3 Bispecific Antibody, As Monotherapy in Patients with Relapsed/Refractory Multiple

Clinical Characteristics and Prognostic Analysis of Non-Amyloid Monoclonal Gammopathy of Renal Significance (MGRS) in China

Rituximab Plus Bortezomib for Refractory and Relapsed Warm Autoimmune Hemolytic Anemia：a Prospective, Single-Arm, Phase Ⅱ Trial

Exploration of B and T Cell Receptor Repertoires Reveals Distinct Mechanisms in Pure Red Cell Aplasia, Autoimmune Hemolytic Anemia, and Aplastic Anemia

Adding Hetrombopag to Cyclosporine a to Patients with Newly Diagnosed Transfusion-Dependent Non-Severe Aplastic Anemia-a Prospective Phase 2 Study

Transcriptomic Profile of Peripheral Blood Mononuclear Cells in Sirolimus-Sensitive Acquired Pure Red Cell Aplasia Patients

STK10 Mutation Block Erythropoiesis in Acquired Pure Red Cell Aplasia Via Down-Regulated the Ribosome Biosynthesis

The Change of Complement Deposition after Complement Inhibitor Treatment in Paroxysmal Nocturnal Hemoglobinuria Patients

Identification of HLA Class I Alleles in Patients with Paroxysmal Nocturnal Hemoglobinuria with Different Clone Sizes

Ixazomib, Pomalidomide and Dexamethasone (IxaPD) Pan-Oral Regimen in the Treatment of Refractory and Relapsed Multiple Myeloma

COVID-19 Vaccine Acceptance/Hesitancy and Influence on Infection in Patients with Multiple Myeloma: A National-Wide Multicenter Survey in China

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only